1. Home
  2. ENHA vs VTVT Comparison

ENHA vs VTVT Comparison

Compare ENHA & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enhanced Group Inc. Class A Common Stock

ENHA

Enhanced Group Inc. Class A Common Stock

N/A

Current Price

$7.10

Market Cap

114.5M

ML Signal

N/A

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

N/A

Current Price

$16.36

Market Cap

104.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENHA
VTVT
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.5M
104.9M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
ENHA
VTVT
Price
$7.10
$16.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$22.33
★ $56.00
AVG Volume (30 Days)
★ 211.6K
13.5K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$118.94
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.03
$16.19
52 Week High
$14.09
$44.00

Technical Indicators

Market Signals
Indicator
ENHA
VTVT
Relative Strength Index (RSI) 57.45 15.32
Support Level $6.30 N/A
Resistance Level $14.09 $34.65
Average True Range (ATR) 1.29 1.40
MACD -0.25 -0.49
Stochastic Oscillator 32.89 0.00

Price Performance

Historical Comparison
ENHA
VTVT

About ENHA Enhanced Group Inc. Class A Common Stock

Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: